Robert Stefanovich, serving as the Chief Financial Officer for Cryoport, Inc. (NASDAQ: CYRX), executed a notable divestment of company equity on June 4, 2026. The transactions resulted in total proceeds of $2,756,983. According to a filing submitted to the Securities and Exchange Commission, Mr. Stefanovich disposed of 169,427 shares of Cryoport common stock. The shares were sold at a weighted average price of $16.2724 per share. These sales were executed across multiple transactions, with prices ranging from $16.05 to $16.70 per share, inclusive. The timing of these sales coincides with the stock trading near its 52-week high of $16.73. This price level follows a remarkable 122% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. For deeper insights, investors can access a comprehensive Pro Research Report on CYRX, one of 1,400+ available on the platform.
Following these transactions, Mr. Stefanovich directly holds 109,850 shares of Cryoport common stock. The report detailing these transactions was filed on June 8, 2026.
In other recent news, CryoPort reported its first-quarter fiscal 2026 earnings with revenue reaching $47.8 million, surpassing both company and consensus estimates of $44.87 million. Despite the revenue beat, the company posted a larger-than-expected loss per share of -$0.25, compared to the anticipated -$0.22. Following these results, CryoPort has raised its revenue guidance for fiscal 2026, suggesting an optimistic outlook for future growth. Analysts have responded positively to these developments, with KeyBanc and BTIG both raising their price targets to $17, citing improved revenue visibility and strong quarterly results. Needham also increased its price target to $15, acknowledging the broad-based strength across CryoPort’s business. The firms maintained their favorable ratings, with KeyBanc and BTIG keeping an Overweight and Buy rating, respectively, and Needham maintaining a Buy rating. These changes reflect the analysts’ confidence in CryoPort’s potential for continued expansion and margin improvement through 2028.